Spots Global Cancer Trial Database for Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
Official Title: A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors
Study ID: NCT00880308
Interventions
Study Description
Brief Summary: This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Pittsburgh Medical Center SC, Pittsburgh, Pennsylvania, United States
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5), San Antonio, Texas, United States
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Zürich, , Switzerland
Novartis Investigative Site, Leicester, , United Kingdom
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
